|Articles|August 1, 2019
- Pharmaceutical Executive-08-01-2019
- Volume 39
- Issue 8
Pharmaceutical Executive, August 2019 Issue (PDF)
Click the title above to open the Pharmaceutical Executive August 2019 issue in an interactive PDF format.
Advertisement
Articles in this issue
over 6 years ago
A Look Back & Forward on Innovationover 6 years ago
Routes to Exclusivity in Cell-Based Therapy Developmentover 6 years ago
Gene Therapy: Managing the Clinical Trial Minefieldsover 6 years ago
The Call to Cure: Geoff MacKay, AVROBIOover 6 years ago
Four Takeaways from the Zolgensma Pricing Stormover 6 years ago
FDA Faces ‘Explosion’ in Growth of Gene Therapiesover 6 years ago
Mapping Out the Future of Cell and Gene Therapyover 6 years ago
High-Stakes Manufacturing: Mitigating the Risksover 6 years ago
Gene Therapy: How ‘Advanced’ is Europe?over 6 years ago
Luxturna: A Vision for Curative Therapy AccessNewsletter
Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on PharmExec
1
Mark Cuban Pushes for Generic Drug Fee Waivers, as Cost Plus Drugs Eyes US Manufacturing Expansion
2
Report: Richard Pazdur Out as Director of CDER
3
FDA Appoints Tracy Beth Høeg as Acting Director of CDER
4
Five Steps for Successful CGT Commercialization Through Health Systems Partnerships
5
